Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Trial Details

NCT ID

NCT06696833

Phase

EARLY_PHASE1

Sponsor

The First Affiliated Hospital of Soochow University

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

• QH10304-BAL-01
• Fludarabine
• Cyclophosphamide

Locations (sample)

• Suzhou, China, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

• Age ≥14 years, gender not specified;
• Diagnosed with B-ALL according to the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue tumors (2022 version);
• Meet the diagnosis of relapsed/refractory leukemia, excluding isolated extramedullary relapse; For relapsed or refractory B-ALL, including any of t…
• Flow cytometry confirms positive CD19 expression in leukemia cells；

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.